These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 18710791)
1. Multiple sclerosis: could it be an epigenetic disease? Kürtüncü M; Tüzün E Med Hypotheses; 2008 Dec; 71(6):945-7. PubMed ID: 18710791 [TBL] [Abstract][Full Text] [Related]
2. Epigenetic mechanisms in multiple sclerosis and the major histocompatibility complex (MHC). Burrell AM; Handel AE; Ramagopalan SV; Ebers GC; Morahan JM Discov Med; 2011 Mar; 11(58):187-96. PubMed ID: 21447278 [TBL] [Abstract][Full Text] [Related]
3. An association study of two functional promotor polymorphisms in the myeloperoxidase (MPO) gene in multiple sclerosis. Lundmark F; Salter H; Hillert J Mult Scler; 2007 Jul; 13(6):697-700. PubMed ID: 17613595 [TBL] [Abstract][Full Text] [Related]
4. Inflammatory signalling as mediator of epigenetic modulation in tissue-specific chronic inflammation. Bäckdahl L; Bushell A; Beck S Int J Biochem Cell Biol; 2009 Jan; 41(1):176-84. PubMed ID: 18793748 [TBL] [Abstract][Full Text] [Related]
7. [Epigenetics-related diseases and analytic methods]. Soejima H Rinsho Byori; 2009 Aug; 57(8):769-78. PubMed ID: 19764412 [TBL] [Abstract][Full Text] [Related]
8. Gender bias in autoimmune diseases: X chromosome inactivation in women with multiple sclerosis. Knudsen GP J Neurol Sci; 2009 Nov; 286(1-2):43-6. PubMed ID: 19411081 [TBL] [Abstract][Full Text] [Related]
9. Epigenetics in multiple sclerosis susceptibility: difference in transgenerational risk localizes to the major histocompatibility complex. Chao MJ; Ramagopalan SV; Herrera BM; Lincoln MR; Dyment DA; Sadovnick AD; Ebers GC Hum Mol Genet; 2009 Jan; 18(2):261-6. PubMed ID: 19098025 [TBL] [Abstract][Full Text] [Related]
10. Histone H2A ubiquitination in transcriptional regulation and DNA damage repair. Zhou W; Wang X; Rosenfeld MG Int J Biochem Cell Biol; 2009 Jan; 41(1):12-5. PubMed ID: 18929679 [TBL] [Abstract][Full Text] [Related]
11. Epigenetic histone acetylation modifiers in vascular remodelling: new targets for therapy in cardiovascular disease. Pons D; de Vries FR; van den Elsen PJ; Heijmans BT; Quax PH; Jukema JW Eur Heart J; 2009 Feb; 30(3):266-77. PubMed ID: 19147603 [TBL] [Abstract][Full Text] [Related]
12. Epigenetic Modifications and Therapy in Multiple Sclerosis. Aslani S; Jafari N; Javan MR; Karami J; Ahmadi M; Jafarnejad M Neuromolecular Med; 2017 Mar; 19(1):11-23. PubMed ID: 27382982 [TBL] [Abstract][Full Text] [Related]
13. Epigenetic mechanisms in health and disease. van der Maarel SM Ann Rheum Dis; 2008 Dec; 67 Suppl 3():iii97-100. PubMed ID: 19022824 [TBL] [Abstract][Full Text] [Related]
14. The potential role of epigenetic modifications in the heritability of multiple sclerosis. Zhou Y; Simpson S; Holloway AF; Charlesworth J; van der Mei I; Taylor BV Mult Scler; 2014 Feb; 20(2):135-40. PubMed ID: 24493701 [TBL] [Abstract][Full Text] [Related]
15. Epigenetics and miRNAs in the diagnosis and treatment of multiple sclerosis. Koch MW; Metz LM; Kovalchuk O Trends Mol Med; 2013 Jan; 19(1):23-30. PubMed ID: 23153574 [TBL] [Abstract][Full Text] [Related]
16. Epigenetic modification induced by hepatitis B virus X protein via interaction with de novo DNA methyltransferase DNMT3A. Zheng DL; Zhang L; Cheng N; Xu X; Deng Q; Teng XM; Wang KS; Zhang X; Huang J; Han ZG J Hepatol; 2009 Feb; 50(2):377-87. PubMed ID: 19070387 [TBL] [Abstract][Full Text] [Related]
17. Epigenetic research in multiple sclerosis: progress, challenges, and opportunities. Zheleznyakova GY; Piket E; Marabita F; Pahlevan Kakhki M; Ewing E; Ruhrmann S; Needhamsen M; Jagodic M; Kular L Physiol Genomics; 2017 Sep; 49(9):447-461. PubMed ID: 28754822 [TBL] [Abstract][Full Text] [Related]
18. The tale of histone modifications and its role in multiple sclerosis. He H; Hu Z; Xiao H; Zhou F; Yang B Hum Genomics; 2018 Jun; 12(1):31. PubMed ID: 29933755 [TBL] [Abstract][Full Text] [Related]